The IL-12 cytokin factory is successful in targeting difficult to treat cancer

A team of researchers from the Rice Biotech starting pad at the University of Rice developed an implantable “cytokin factory”, which safely triggers strong immune answers against cancer difficult to treat, including metastatic melanoma, pancreas and colorectal tumors.

The study, published in, describes in detail how the device immunoted near the micro-environment of the tumor containing cells designed for local release of interleukin-12 (IL-12)-“IL-12 cytokines factory”-successfully induces recruitment of specialized immune cells called precursor TPex cells (TPEX cells). This recruitment of TPEX cells causes a large, permanent Population of T cells focused on cancer with a wide molecular profile, both in insulation and in an increased method in combination with other immunotherapy approaches.

IL-12 cytokin factories in combination with control point inhibitors have successfully eliminated local and distal tumors in pre-clinical metastatic models melanoma and colorectal cancer and pancreas. In addition to this solid effectiveness signal, the IL-12 cytokin factory showed safety in both mouse and inhuman models.

This published research will constitute the basis for studying the new use of drugs (Ind) from the US FDA at the beginning of 2026, and RBL LLC expects to launch a new biotechnology company focused on the groundbreaking technology of the IL-12 cytokin factory factory.

“We designed the IL-12 cytokin factory to increase the approach of immunotherapy while minimizing toxicity, a critical need in the treatment of particularly aggressive cancers,” said omid Veiseh, a professor of bio-onyardy, director of the Faculty of Rice Biotech Launch Pad and senior correspondence author of the publication. “IL-12 is particularly influential in comparison with other cytokines, because our studies show that other cytokines primarily recruit homogeneous T cells and show reduced effectiveness at a time, while IL-12 generates a more solid anti-cancer response by recruiting a more permanent, broader consequence of T-Targeting cells.

“We are extremely grateful to ARPA-H for their support in the development of this breakthrough project and we hope that this technology will significantly affect the life of patients with cancer, improving effectiveness Immunotherapy approaches in the clinic. “

The use of the cellular immune system to direct solid tumors is a common, but often burdened approach to fighting cancer, because the associated challenge of effective treatment without toxicity remains elusive. Our study shows not only the effectiveness of this technology in pre -clinical models, but also its safety profile, which is a key aspect when we are approaching clinical trials. This study is an important step forward in the pursuit of more effective treatment of patients fighting metastatic cancer. “

Nathan reticker-Flynn, assistant to the professor of otolaryngology at the Stanford University

The research was supported by the Avenge Bio Sponsored Award for Rice, Rice, Institute of Research on Prevention Prevention Institute of Texas (RR160047), the National Institutes of Health (R01CA272769, DP2 AI17915) and ARPA-H (AY1AX000003). The content is only the responsibility of the authors and does not necessarily represent the official views of the financing institutions.